Perioperative Atezolizumab Plus Chemotherapy More Than Doubles Event-Free Survival in Resectable Stage II–IIIB NSCLC

Patients with resectable stage II–IIIB non–small cell lung cancer (NSCLC) who received perioperative atezolizumab查看药品详情 plus platinum-based chemotherapy (搜索)搜索该药品 achieved a median event-free survival of 62.8 months, compared with 34.9 months for those treated with chemotherapy alone, according to final results from the phase III IMpower030 (搜索)搜索该药品 trial. The data were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea (Abstract OA04.03).

The roughly 28-month separation between the two arms represents one of the most detailed long-term pictures to date of how perioperative immunotherapy performs in early-stage lung cancer, a setting where recurrence after surgery has historically been a major concern.

Trial Design and Rationale

IMpower030 (搜索)搜索该药品 was designed to test whether adding an immune checkpoint inhibitor to the standard surgical pathway could alter the natural history of a cancer often detected at an operable stage but still recurring in a large fraction of patients. In the experimental arm, patients received atezolizumab查看药品详情 combined with platinum-based chemotherapy (搜索)搜索该药品 before surgery (neoadjuvant therapy) and continued atezolizumab after surgery as adjuvant treatment. The comparator arm received the same chemotherapy backbone with placebo in place of the immunotherapy agent.

This perioperative design aims to attack the tumor while it is still in the body, priming the immune system against cancer cells before the primary tumor is removed, and then sustaining that immune pressure afterward to eliminate microscopic disease that surgery alone cannot reach.

Pathologic Response and Survival

Beyond the event-free survival data, the trial demonstrated substantially higher rates of pathologic response in tumors removed at surgery. Pathologic complete response — no viable cancer cells identified in the resected specimen — was achieved in 30.6% of patients treated with atezolizumab查看药品详情 plus chemotherapy versus 8.6% of those receiving placebo plus chemotherapy. Major pathologic response, defined as residual viable tumor of 10% or less, was seen in 54.3% versus 24.9%, respectively.

Investigators linked these pathologic findings to the survival benefit through biology: when immunotherapy recruits the body's own T cells to recognize and destroy cancer cells, responding tumors often shrink dramatically or are largely replaced by immune infiltrates and fibrous tissue. Removing a tumor already largely eradicated by the immune system leaves behind fewer viable cells capable of seeding recurrence. The arm with roughly double the rate of major pathologic response also showed the longer event-free survival, reinforcing the view that depth of response before surgery translates into durable clinical benefit.

Statistical Significance and Endpoint Consistency

An important nuance in interpreting the trial is that it did not meet its predefined threshold for statistical significance. Nevertheless, investigators reported improvements across multiple efficacy endpoints, including independent review facility–assessed event-free survival, investigator-assessed event-free survival, disease-free survival, and overall survival. The consistency of benefit across independently and investigator-assessed measures, and across endpoints capturing both recurrence and death, strengthens confidence that the observed advantage reflects a real treatment effect.

Benjamin Solomon, M.D., of the Peter MacCallum Cancer Centre (搜索)搜索该词条 in Melbourne, Australia, the presenting author, said the long-term findings demonstrate clinically meaningful improvements across several important outcomes and further support the role of perioperative immunotherapy for patients with resectable NSCLC.

Safety and Surgical Feasibility

Safety and surgical feasibility were central questions for a perioperative strategy, since any therapy given before surgery must not compromise the ability to perform a potentially curative operation. In IMpower030 (搜索)搜索该药品, surgical cancellation rates remained low and were similar between the two treatment groups, indicating that preoperative atezolizumab查看药品详情 did not prevent patients from proceeding to surgery. No new safety signals were identified, and the side-effect profile was consistent with what is already known about atezolizumab and platinum-based chemotherapy (搜索)搜索该药品.

Investigators noted that adverse events occurred more frequently during the neoadjuvant phase than during the adjuvant phase in both treatment arms, a pattern consistent with the combined intensity of chemotherapy and immunotherapy delivered before surgery and with the general tendency of treatment-related toxicity to cluster early in a treatment course.

Implications for Clinical Practice

Non–small cell lung cancer remains the leading cause of cancer death worldwide, and even among patients whose disease is caught early enough for surgery, relapse rates have historically been discouragingly high. The addition of immune checkpoint inhibitors to perioperative treatment represents a shift from a strategy built almost entirely on surgery to one that enlists the immune system as an active partner in eradicating disease.

For clinicians managing resectable stage II–IIIB NSCLC, the final IMpower030 (搜索)搜索该药品 results add weight to the growing body of evidence supporting perioperative immunotherapy. The pathologic response findings offer an early, measurable signal of benefit, while the event-free and overall survival data provide longer-term reassurance that early responses translate into extended periods without recurrence. Questions remain about which patients benefit most, how long adjuvant treatment should continue, and how best to sequence systemic therapy with surgery — areas the lung cancer community continues to refine.